B+
Overall grade
B
Financial quality
The sleeper story is structural expense transformation - THC is rebuilding hospital workflows with automation and AI, not just cutting costs. This explains how they can guide 10% core EBITDA growth despite a $250M ACA headwind. The binding constraint is volume momentum - hospital admissions flattened and USPI growth guidance dropped back to long-term targets after 7.5% delivery. Most revealing quote: 'We are tackling expense management more structurally in anticipation of the next few years' - they're preparing for a tougher operating environment ahead. My view changes if hospital volumes don't recover in Q1 2026 or if their 'structural' expense savings fail to materialize with specific dollar targets.
The 30-second version
- Hospital margin expansion accelerated despite ACA headwinds - the structural expense story is real
- 10% normalized core EBITDA growth guidance is aggressive but backed by $875M CapEx surge
- USPI same-store growth guidance dropped to 3-6% from 7.5% actual - capacity or demand?
What changed this quarter
| Metric | Prior | This quarter |
|---|---|---|
| Net Operating Revenues | $5.3B (vs $5.0B Q3 2024) | $5.5B (vs $4.9B Q4 2024) |
| Consolidated Adjusted EBITDA | $1.1B (12% YoY) | $1.183B (13% YoY) |
| Adjusted EBITDA Margin | 20.8% (+170 bps YoY) | 21.4% (+continuous improvement) |
| Hospital Adjusted EBITDA | $607M (13% YoY) | $603M (16% YoY) |
| USPI Adjusted EBITDA | $492M (12% YoY) | $580M (9% YoY) |
| USPI Same-Facility Revenue Growth | 8.3% (vs 6.1% Q2) | 7.2% (5.5% price, 1.6% volume) |
| Hospital Revenue per Adjusted Admission | 5.9% YoY | 7.5% YoY |
| Free Cash Flow | $778M Q3 | $367M Q4 |
Accountability tracked
8 new promises made5 narrative shifts flagged7 prior promises graded
Inside the full report
The complete write-up covers the full promise ledger with kept/missed calls, disclosure-quality scoring, the metrics-vanished check, verification items, and the questions to ask next quarter.
Subscribe to Call Sheet Daily →